Kenichi Akao1, Tomohiro Fujiyama1, Sayoko Ohkawara1, Midori Goto1, Toru Watanabe1, Makoto Hirosawa1, Ai Kawahara1, Noriaki Kitamura1, Tsukasa Nakanishi1, Takahiro Yamaguchi2, Aya Tanaka1, Takefumi Katsuragi3, Takehiro Higashi1, Hiroaki Morimoto1, Junichi Tsukada1 (1.Department of Hematology, UOEH, Kitakyushu, Japan, 2.Department of Palliative Care Hematooncology, Wakamatsu Hospital, UOEH, Kitakyushu, Japan, 3.Kitakyushu General Hospital, Kitakyushu, Japan)
Session information
Poster Session
Fri.Oct,11
Poster Session 1-8 ALL: Novel Therapeutic Agents
Fri. Oct 11, 2019 5:40 PM - 6:20 PM Poster (Tokyo International Forum, B2F Hall E)
Chair: Takeshi Saito (Div. Clinical Oncology/Hematology, Jikei University, Tokyo, Japan)
[PS1-8-2] Successful blinatumomab bridging treatment for a patient with ponatinib refractory Ph+ ALL
Naoko Hiranuma, Yusuke Koba, Shumpei Mizuta, Noriko Yamane, Takao Komai, Kazuhiro Bandai, Kensuke Fujiwara, Mizuki Hyuga, Takahito Kawata, Naoya Ukyo, Akira Tamekane, Mitsumasa Watanabe (Hematology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan)
Satoshi Morishige, Yoshitaka Yamasaki, Shuki Oya, Takayuki Nakamura, Maki Yamaguchi, Kazutoshi Aoyama, Ritsuko Seki, Fumihiko Mouri, Koichi Osaki, Koji Nagafuji (Division of Hematology and Oncology, Kurume University., Fukuoka, Japan)
[PS1-8-4] Sequential administration with inotuzumab and blinatumomab for a patient with relapsed ALL
Shino Fujimoto, Shuichi Mizuta, Tomoyuki Sakai, Hiroshi Kawabata, Toshihiro Fukushima, Yasufumi Masaki (Hematology and Immunology, Medicine, Kanazawa Medical University, Ishikawa)
Kanae Fujii, Shuro Yoshida, Tomonori Shimokawa, Yayoi Matsuo, Takuro Kuriyama, Tetsuya Eto (Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan)
Ryo Saito, Atsushi Satake, Yuka Ishii, Jun Ichikawa, Akiko Konishi, Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Shinya Fujita, Tomoki Ito, Shosaku Nomura (Department of Hematology, Kansai Medical University Hospital, Osaka, Japan)
Hideko Goto1, Nobuhiro Kanemura1, Naoki Katsumura1, Hisashi Tsurumi2 (1.Department of Hematology, Chuno Kosei Hospital, Gifu, Japan, 2.Matsunami General Hospital)
Shiho Wakase1, Takanori Teshima2, Hikaru Okada1, Cynthia Qi3, Eric Wu3, Hongbo Yang3, Xinglei Chai3, Yoshinobu Kanda4 (1.Novartis Pharma K.K., Minato-ku, Tokyo, Japan, 2.Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan, 3.Analysis Group, Inc., Boston, Massachusetts, United States of America, 4.Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan)